Number (%) of patients in the AIM trial in RAPID3 versus DAS28 disease activity/severity categories at 52 weeks.
| RAPID3 Severity | |||||
|---|---|---|---|---|---|
| Abatacept Treatment Group | High, n (%) | Moderate, n (%) | Low, n (%) | Remission, n (%) | Total, n (%) |
| DAS28 Activity | |||||
| High | 59 (80) | 14 (19) | 0 | 1 (< 1) | 74 (20) |
| Moderate | 58 (29) | 80 (40) | 42 (21) | 18 (9) | 198 (53) |
| Low | 4 (11) | 14 (38) | 10 (27) | 9 (24) | 37 (10) |
| Remission | 2 (3) | 15 (23) | 18 (28) | 30 (46) | 65 (17) |
| Total | 123 (33) | 123 (33) | 70 (19) | 58 (16) | 374 (100) |
| Kappa = 0.28; weighted kappa = 0.42. | |||||
| Control treatment group | |||||
| DAS28 Activity | |||||
| High | 80 (78) | 17 (17) | 5 (5) | 0 | 102 (56) |
| Moderate | 23 (31) | 33 (45) | 12 (16) | 6 (8) | 74 (40) |
| Low | 1 (33) | 0 | 0 | 2 (67) | 3 (2) |
| Remission | 0 | 1 (25) | 1 (25) | 2 (50) | 4 (2) |
| Total | 104 (56) | 51 (28) | 18 (10) | 10 (5) | 183 (100) |
| Kappa = 0.33; weighted kappa = 0.40. | |||||
AIM: Abatacept in Inadequate Response to Methotrexate; RAPID3: Routine Assessment of Patient Index Data; DAS28: 28-joint Disease Activity Score.